Sugi Predict

Sugi Predict / Compounds / SCHEMBL545449

SCHEMBL545449

SCHEMBL545449

CN1CCN(Cc2cc(N)cc(C(F)(F)F)c2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.53
▸ NR1H2 P55055 1/20 0.52
▸ CHKA P35790 2/20 0.51
▸ ALDH1A1 P00352 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ MAPT P10636 1/20 0.48
▸ CYP2D6 P10635 3/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ USP2 O75604 2/20 0.45
▸ CASP1 P29466 1/20 0.45
▸ CASP5 P51878 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ MC4R P32245 1/20 0.44
▸ GAA P10253 1/20 0.43
▸ TSHR P16473 1/20 0.42
▸ DDR1 Q08345 3/20 0.42
▸ DDR2 Q16832 2/20 0.42
▸ ABL1 P00519 1/20 0.42
▸ HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29777509 1.00 LMNA (0.53) LMNANR1H2CHKAALDH1A1KDM4E
SCHEMBL10819405 0.89 CHKA (0.57) LMNANR1H2CHKAALDH1A1KDM4E
SCHEMBL29543344 0.88 ALDH1A1 (0.47) LMNANR1H2ALDH1A1KDM4EMAPT
SCHEMBL545422 0.88 ALDH1A1 (0.47) LMNANR1H2ALDH1A1KDM4EMAPT
SCHEMBL4947573 0.86 ALDH1A1 (0.56) LMNANR1H2CHKAALDH1A1KDM4E
SCHEMBL4935986 0.86 ALDH1A1 (0.54) LMNACHKAALDH1A1KDM4ECYP2D6
SCHEMBL545692 0.86 ALDH1A1 (0.58) LMNACHKAALDH1A1KDM4ECYP2D6
SCHEMBL29967920 0.86 ALDH1A1 (0.58) LMNACHKAALDH1A1KDM4ECYP2D6
SCHEMBL545978 0.84 ALDH1A1 (0.60) LMNAALDH1A1KDM4ECYP2D6CYP3A4
Hydrochloric Acid SCHEMBL30349712 0.84 ALDH1A1 (0.56) LMNACHKAALDH1A1KDM4ECYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617801-B2 Tetrahydrothieno pyridine derivatives as DDRS inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-05-05 — — US disclosed
EP-4313292-B1 INDOLINE DERIVATIVES AS DDR1 AND DDR2 INHIBITORS CHIESI FARM SPA (IT) 2026-02-18 — — EP disclosed
EP-4387963-B1 PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1 REDX PHARMA LTD (GB) 2025-12-24 — — EP disclosed
US-20250177382-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2025-06-05 — — US disclosed
EP-4313293-B1 TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-05-07 — — EP disclosed
EP-4313994-B1 TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-03-05 — — EP disclosed
EP-4506349-A2 TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2025-02-12 — — EP disclosed
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP disclosed
US-20240391936-A1 TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-11-28 — — US disclosed
US-20240317758-A1 NEK7 INHIBITORS Halia Therapeutics, Inc. 2024-09-26 — — US disclosed
US-20060241115-A1 Compounds and methods of use AMGEN INC. 2006-10-26 — — US disclosed
EP-1713484-A2 COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2006-10-25 — — EP disclosed
US-20060217380-A1 Heteroaryl-substituted alkyne compounds and method of use AMGEN INC. 2006-09-28 — — US disclosed
EP-1689376-A2 DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2006-08-16 — — EP disclosed
WO-2006044823-A2 HETEROARYL-SUBSTITUTED ALKYNE COMPOUNDS AND METHOD OF USE AMGEN INC. (US) 2006-04-27 — — WO disclosed
WO-2006039718-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2006-04-13 — — WO disclosed
US-20060009453-A1 Protein kinase modulators and method of use AMGEN INC. 2006-01-12 — — US disclosed
WO-2005113494-A2 NITROGENATED HETEROCYCLIC DERIVATIVES AS PROTEIN KINASE MODULATORS AND USE FOR THE TREATMENT OF ANGIOGENESIS AND CANCER AMGEN INC. (US) 2005-12-01 — — WO disclosed
WO-2005070891-A2 COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2005-08-04 — — WO disclosed
WO-2005051366-A2 DIARYL UREA DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2005-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240391936-A1 TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS DDR1, DDR2, DDRGK1 LMNA 1580/4885NR1H2 2250/4885CHKA 2381/4885
US-12617801-B2 Tetrahydrothieno pyridine derivatives as DDRS inhibitors DDR1, DDR2, DDRGK1 LMNA 557/4885NR1H2 680/4885CHKA 730/4885
US-20060241115-A1 Compounds and methods of use HGF, HGFAC, MET LMNA 3258/4885NR1H2 986/4885CHKA 1074/4885
US-20060009453-A1 Protein kinase modulators and method of use PHKG1, PRKCH, BMP2K LMNA 3974/4885NR1H2 2484/4885CHKA 421/4885
US-20250177382-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 LMNA 130/4885NR1H2 1673/4885CHKA 1002/4885
US-20240317758-A1 NEK7 INHIBITORS NEK7, NEK5, NEK1 LMNA 196/4885NR1H2 2147/4885CHKA 793/4885
US-20060217380-A1 Heteroaryl-substituted alkyne compounds and method of use IRAK3, IRAK1, MAP3K1 LMNA 1665/4885NR1H2 1088/4885CHKA 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.